Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Lombard Medical, Inc. (EVARF)
Didcot, GB
Lombard Medical, Inc. is a medical technology firm specializing in the creation, production, and distribution of endovascular stent-grafts designed for the repair of aortic aneurysms. The company serves a global market, with operations in the United States, United Kingdom, Germany, Japan, and other international regions. Its leading offering, Aorfix, is an endovascular stent-graft specifically engineered to address abdominal aortic aneurysms (AAAs) where the aneurysm's neck exhibits significant angulation, up to 90 degrees. Other solutions include the Altura endovascular stent graft system, tailored for more conventional AAA anatomies. Furthermore, Lombard Medical provides sophisticated delivery mechanisms: the Aorflex system ensures precise deployment of Aorfix within the abdominal aorta, while the IntelliFlex LP system further enhances the accuracy and control during Aorfix placement and deployment. The firm distributes its products through both its proprietary sales force and a network of distributors, primarily targeting state- or government-operated hospitals. Established in 2000, Lombard Medical, Inc. maintains its corporate headquarters in Didcot, United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -99.09% | -99.99% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%-19.5%
-
EPS growth Medical - Devices: +28.5%+27.7%
-
FCF margin FCF growth · Medical - Devices: +30.9%-266.7%
-
EBIT margin Medical - Devices: +6.2%-251.2%
-
ROIC Medical - Devices: +3.3%-120.0%
-
Share dilution Medical - Devices: 0.0%+13.6%
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-1.15×
| Metric |
Dec 2016 actual |
Dec 2017 actual |
|---|---|---|
| Revenue |
12.17M
est: 12.17M (+0.0%)
|
13.72M
est.
|
| EBITDA |
-28.07M
est: -12.17M (-130.7%)
|
-13.72M
est.
|
| EBIT |
-30.57M
est: -12.17M (-151.2%)
|
-13.72M
est.
|
| Net Income |
-31.04M
|
—
est.
|
| SGA |
22.81M
est: 25.50M (-10.5%)
|
28.75M
est.
|
| EPS |
-1.54
|
—
est.
|
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Peter Phillips | Chief Technology Officer | 292.1K | — |
| Andrew Debbage | Vice President of Operations | — | — |
| Jonathan Hornsby | Vice President of Sales & Marketing | — | male |
| Kate Forster | Vice President of Human Resources | — | female |
| Kurt Lemvigh | Chief Executive Officer | — | male |
| Paul Hardwick | Vice President of Sales | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EVARF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
